Catalog No.
DHD10806
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Concentration
4.55 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15391
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.94mM Citric acid, 16.7mM Trisodium citrate dihydrate, 6.2% sucrose, pH 6.5,0.01% Tween 80
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ADCT-402, RB4v1.2-SG-3249, CAS: 1875032-68-0
Clone ID
Loncastuximab
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma, PMID: 33211842
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia, PMID: 32012214
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, PMID: 31685491
Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma, PMID: 30543588
Antibodies to watch in 2020, PMID: 31847708
Loncastuximab Tesirine: First Approval, PMID: 34143407
Loncastuximab Tesirine-lpyl, PMID: 34131694
Loncastuximab Tesirine, PMID: 34014627
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies, PMID: 29298756
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial, PMID: 33989558
FDA approves ADC Therapeutics' loncastuximab tesirine, ushering in a new cytotoxic payload, PMID: 33981088
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy, PMID: 32543981
The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates, PMID: 32669316
Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies, PMID: 32267477
Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma, PMID: 34017197
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress, PMID: 34090506
The era of CD19-directed therapy in diffuse large B-cell lymphoma, PMID: 33989556
For research use only. Not for human or drug use.
